ABSTRACT
Haemodynamic monitoring is necessary for the effective management of critically ill cardiac patients. Pulmonary artery catheterization has been used for monitoring the circulation, for measurement of intracardiac pressures and to estimate preload and afterload. However, pressures may not be accurate reflection of the circulation and simultaneous measurement of volumes would improve patient treatment. However, measurement of cardiac volumes especially of the right ventricle is difficult in everyday clinical practice In this work we propose the use of pulmonary artery catheter (PAC) with ultrasonic sensors built on it, to calculate the right ventricular end-diastolic (RVEDV) and end-systolic volume (RVESV). This is achieved by using the Ultrasonic (US) beam, to measure the distances between the transducers on the catheter and the RV walls. These distances, will be used as an input to a Volume calculating algorithm, which finally provides the RVEDV and RVESV, using a Neural Network (NN). For that reason, we have used cardiac Magnetic Resonance Imaging (MRI) and have modeled the catheter and the US transducers, to get as input the distances to the surface of the cavity. With these distances, and the known cardiac volumes (calculated using MR images) we trained and validated a NN for volume calculation. The results show that the algorithm accurately calculates the RVEDV. For the RVESV, greater deviations are observed between values calculated with our algorithm and cardiac MRI.
Subject(s)
Catheterization, Swan-Ganz , Computer Simulation , Models, Cardiovascular , Neural Networks, Computer , Ventricular Function, Right/physiology , Humans , Reproducibility of Results , Stroke VolumeABSTRACT
OBJECTIVE: Acute non-traumatic bone marrow edema (BME) in the knee is a common clinical problem. The aim of the present study is to present the MR imaging findings of the uncommon transient migratory pattern of this syndrome. MATERIALS AND METHODS: Twenty-two patients (21 men, 1 woman, age range 35-73 years, mean 49.4+/-7.6) who presented with pain in the knee joint (ranging from 2 weeks to 6 months) and BME in the MR imaging examination, were included in the study. In all cases, the knee joint BME was either preceded or followed by another site of BME in the same or another joint. All patients were studied with plain X-rays and MR imaging at presentation and with MR imaging after resolution of symptoms. RESULTS: The eight patients with initial involvement in the knee showed migration either intra-articularly (5), or/and in the contralateral knee (2) and only 1 case showed migration to the ipsilateral hip joint. In two patients the BME shifted from the hip first to the foot and then to the knee. The median migration period was 4 months for the second involvement in all patients and 3 months for the third involvement (10 patients). CONCLUSIONS: The present study reports the largest series of patients with regional migratory osteoporosis involving the knee. In most of the cases, shifting of BME remains in the joint or moves to the contralateral knee. In only one case the BME shifted from the knee elsewhere. All lesions were transient.
Subject(s)
Bone Marrow Diseases/diagnosis , Edema/diagnosis , Knee Joint/pathology , Magnetic Resonance Imaging/methods , Osteoporosis/diagnosis , Adult , Aged , Female , Humans , Male , Middle Aged , SyndromeABSTRACT
PURPOSE: To evaluate the efficacy and toxicity of the gemcitabine plus vinorelbine combination in pretreated patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Thirty-five pretreated patients (median age 59 years, PS: 0--1 in 97% and 2 in 3%) were treated with gemcitabine (1100 mg/m(2)) and vinorelbine (25mg/m(2)) on d1 and d8 every 3 weeks. Seven (20%) patients were treated with two prior regimens and 20 (57%) were refractory to front-line chemotherapy. RESULTS: In an intention-to-treat analysis two (6%) partial responses (PR) were observed with a duration of 5.6 and 11.1 months. Stable disease (SD) was documented in 8 (23%) patients and progressive disease (PD) in 25 (71%). The overall median survival was 4.5 and the 6 months survival rate was 42.6%. Grades 3--4 neutropenia and thrombocytopenia were observed in 25 and 14% of the patients, respectively. Non-hematological toxicity consisted of grade 2 neurotoxicity occurring in 14% of the patients and grades 2--3 fatigue in 17%. Febrile neutropenia was observed in three (8.6%) patients and one of them died from sepsis. CONCLUSION: The combination of gemcitabine plus vinorelbine cannot be considered as an effective salvage treatment in pretreated patients with SCLC.
